Close Menu

NEW YORK (GenomeWeb) – Roche announced today it will work with Merck to develop a pan-cancer companion diagnostic test to assess whether patients have mismatch repair deficiency in their tumors and are eligible for receiving Merck's checkpoint inhibitor Keytruda (pembrolizumab).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.